Superior Glycemic Control with Taspoglutide, a Once-Weekly Human GLP-1 Analog, Compared with Twice Daily Exenatide in Type 2 Diabetes (T2DM) Inadequately Controlled on Oral Agents: The T-emerge 2 Trial

被引：0

作者：

Rosenstock, Julio

Balas, Bogdan

Charbonnel, Bernard

Bolli, Geremia B.

Boldrin, Mark

Ratner, Robert

Balena, Raffaella

机构：

来源：

DIABETES | 2010年 / 59卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：A17 / A17

页数：1

共 50 条

[1] Superior glycaemic control with taspoglutide, a once-weekly human GLP-1 analogue, compared with twice daily exenatide in type 2 diabetes: the T-emerge 2 Trial
Bolli, G. B.
Rosenstock, J.
Balas, B.
Charbonnel, B.
Boldrin, M.
Ratner, R.
Balena, R.
DIABETOLOGIA, 2010, 53 : S38 - S38
[2] The Fate of Taspoglutide, a Weekly GLP-1 Receptor Agonist, Versus Twice-Daily Exenatide for Type 2 Diabetes The T-emerge 2 trial
Rosenstock, Julio
Balas, Bogdan
Charbonnel, Bernard
Bolli, Geremia B.
Boldrin, Mark
Ratner, Robert
Balena, Raffaella
DIABETES CARE, 2013, 36 (03) : 498 - 504
[3] Once-Weekly Taspoglutide, a Human GLP-1 Analog, Is Superior to Placebo in Improving Glycemic Control and Body Weight Loss in Obese Patients with Type 2 Diabetes (T2D) Inadequately Controlled with Metformin Monotherapy: Results from the T-emerge 7 Trial
Hollander, Priscilla
Bengus, Monica
Barnett, Anthony
Lasko, Ben
Boldrin, Mark
Balena, Raffaella
Pi-Sunyer, F. Xavier
DIABETES, 2010, 59 : A160 - A160
[4] Once Weekly Taspoglutide, a Human GLP-1 Analog, Is Superior to Sitagliptin in Improving Glycemic Control and Weight Loss in Patients with Type 2 Diabetes (T2D): Results from the T-emerge 4 Trial
Bergenstal, Richard
Forti, Adriana
Chiasson, Jean-Louis
Woloschak, Mike
Boldrin, Mark
Leiter, Lawrence A.
Balena, Raffaella
DIABETES, 2010, 59 : A16 - A16
[5] Taspoglutide, once-weekly human GLP-1 analogue, compared to BID Exenatide improves glucose tolerance and insulin secretion in patients with type 2 diabetes: T-emerge 2 meal tolerance test
Ratner, R.
Rosenstock, J.
Balas, B.
Charbonnel, B.
Bolli, G. B.
Boldrin, M.
Balena, R.
DIABETOLOGIA, 2010, 53
[6] Taspoglutide, a once-weekly human GLP-1 analogue, is superior to Sitagliptin in improving glycaemic control and achieving weight loss in patients with type 2 diabetes: the T-emerge 4 Trial
Chiasson, J. -L
Leiter, L. A.
Forti, A.
Bergenstal, R. M.
Woloschak, M.
Boldrin, M.
Balena, R.
DIABETOLOGIA, 2010, 53
[7] Taspoglutide, a Once-Weekly Human GLP-1Analog, Improves Glucose Tolerance and Insulin Secretion in Patients with Type 2 Diabetes (T2DM): Results of a Meal Tolerance Test from T-emerge 2
Rosenstock, Julio
Balas, Bogdan
Charbonnel, Bernard
Bolli, Geremia B.
Boldrin, Mark N.
Ratner, Robert
Balena, Raffaella
DIABETES, 2010, 59 : A196 - A196
[8] Taspoglutide, a Once-Weekly Human GLP-1 Analog, Provides Comparable Glycemic Control to Insulin Glargine,' with Superior Weight Loss and Less Hypoglycemia in Type 2 Diabetes (T2D): A Phase 3, Open-Label Trial (T-emerge 5)
Nauck, Michael
Horton, Edward
Andjelkovic, Mirjana
Javier Ampudia-Blasco, F.
Boldrin, Mark N.
Balena, Raffaella
DIABETES, 2010, 59 : A16 - A16
[9] Taspoglutide, a Once-Weekly Human GLP-1 Analog, Reduces Appetite and Promotes Weight Loss in Patients With Type 2 Diabetes (T2D): Phase 3 Trial Versus Sitagliptin and Placebo (T-Emerge 4)
Bergenstal, Richard
Forti, Adriana
Chiasson, Jean-Louis
Woloschak, Mike
Boldrin, Mark
Leiter, Lawrence
Balena, Raffaella
OBESITY, 2010, 18 : S156 - S156
[10] Taspoglutide, a Once-Weekly (QW) Human GLP-1 Analog, Reduces Body Weight, Waist and Hip Circumferences, and Decreases Appetite in Patients With Type 2 Diabetes (T2D) Inadequately Controlled With Metformin +/- Thiazolidinedione: Results From the Phase 3 T-Emerge 2 Trial
Rosenstock, Julio
Balas, Bogdan
Charbonnel, Bernard
Bolli, Geremia B.
Boldrin, Mark
Ratner, Robert
Balena, Raffaella
OBESITY, 2010, 18 : S51 - S52

← 1 2 3 4 5 →